Please login to the form below

Not currently logged in
Email:
Password:

Galapagos

This page shows the latest Galapagos news and features for those working in and with pharma, biotech and healthcare.

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

The decision to drop MOR106, a selective IL-17c inhibitor co-developed by MorphoSys and Belgian biotech Galapagos, was taken after an interim analysis of data from the IGUANA trial in ... In July 2018, MorphoSys and Galapagos  handed over all MOR106

Latest news

More from news
Approximately 9 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    Galapagos. Another star performer this year which is breaking the mould of underperforming European biotechs is Galapagos. ... For Galapagos, the partnership massively increases its financial security and firepower, while preserving its independence as a

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    This adds to the good news for Vertex, which saw AbbVie and Galapagos also post disappointing results for their triple therapy candidate.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

  • Deal Watch May 2016 Deal Watch May 2016

    271. Galapagos/ AbbVie. Agreement extension. Cystic fibrosis alliance for development of a triple combination therapy; increase in milestones from $350m to $600m.

  • Deal Watch December 2015 Deal Watch December 2015

    therapy areas such as oncology and, this month inflammatory disease, following the licensing deal with Galapagos for over $2bn. ... Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics